Research programme: phosphodiesterase-4 inhibitors - Curacyte

Drug Profile

Research programme: phosphodiesterase-4 inhibitors - Curacyte

Alternative Names: CD160130

Latest Information Update: 16 Oct 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Curacyte AG
  • Class Antineoplastics
  • Mechanism of Action Apoptosis stimulants; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia

Highest Development Phases

  • Discontinued Chronic lymphocytic leukaemia

Most Recent Events

  • 26 Aug 2011 Discontinued - Preclinical for Chronic lymphocytic leukaemia in Germany (unspecified route)
  • 25 Sep 2007 Preclinical trials in Chronic lymphocytic leukaemia in Germany (unspecified route)
  • 24 Sep 2007 Research programme: phosphodiesetare-4 inhibitors - Curacyte received Orphan Drug status for Chronic lymphocytic leukaemia in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top